insulin glargine

Showing 5 posts of 5 posts found.

Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes

Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …

diabetes_injection

Sanofi’s LixiLan meets target in Phase III diabetes trial

September 16, 2015
Research and Development Lantus, LixiLan, Lixisenatide, Lxyumia, Sanofi, diabetes, insulin glargine, metformin, type 2 diabetes

Sanofi’s Phase III clinical trial of its Lixilan treatment has achieved its primary endpoint in patients with type 2 diabetes, …

UCB

Mixed Phase 3 results for Sanofi and UCB

July 29, 2015
Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III

Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …

Sanofi image

Sanofi sees FDA approval for diabetes drug

February 26, 2015
Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4

US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …

Sanofi image

Sanofi sales lifted by diabetes and rare diseases

February 6, 2015
Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4

Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …

The Gateway to Local Adoption Series

Latest content